Business Context and Reporting Period
Company: Scinai Immunotherapeutics Ltd. (Scinai)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Model: Dual-segment biopharmaceutical company comprising (1) an R&D unit developing inflammation and immunology therapeutics (NanoAbs platform and PC111 asset) and (2) a Contract Development and Manufacturing Organization (CDMO) unit providing services to early-stage biotechs.
Headquarters: Jerusalem, Israel.
Key Financial Metrics
| Metric (USD in thousands) | 2025 | 2024 |
|---|---|---|
| Revenues | $1,311 | $658 |
| Cost of Revenues | $(3,963) | $(1,238) |
| Gross Profit (Loss) | $(2,652) | $(580) |
| Operating Loss | $(7,542) | $(8,638) |
| Net Income (Loss) | $(8,307) | $4,796 |
| Cash and Cash Equivalents | $1,661 | $1,964 |
| Working Capital | $469 | $585 |
| Accumulated Deficit | $(125,846) | $(117,539) |
| Net Cash Used in Operating Activities | $(6,031) | $(6,335) |
Note: 2024 Net Income included a one-time gain of $14.8 million from a troubled debt restructuring with the European Investment Bank (EIB). 2025 results reflect the absence of this non-recurring gain.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 99% to $1.3 million, driven by expanded CDMO activities and customer engagement.
- Profitability Shift: The company returned to a net loss of $8.3 million in 2025 compared to a net income of $4.8 million in 2024. This reversal is primarily due to the absence of the $14.8 million gain on debt restructuring recognized in 2024.
- Operating Expenses: Research and Development (R&D) expenses decreased significantly from $5.5 million to $2.4 million due to reduced allocation of employees and facilities to the R&D unit. Marketing, General, and Administrative (MG&A) expenses remained flat at approximately $2.6 million.
- Capital Structure: In 2024, a significant portion of the EIB loan was converted into preferred shares. In 2025, the company raised approximately $5.7 million through Standby Equity Purchase Agreements (SEPA).
Outlook, Risks, and Contingencies
Going Concern Qualification
The financial statements include a "substantial doubt" going concern qualification. As of December 31, 2025, cash balances of $1.7 million are insufficient to fund planned operations for at least one year. The company requires substantial additional financing to continue operations, advance R&D, and scale the CDMO unit.
Key Risks and Contingencies
- Financing Needs: Continued reliance on equity financing, grants, or debt. Failure to secure funding could force delays or termination of activities.
- PC111 Acquisition: The company holds an option to acquire Pincell S.r.l. (owner of PC111). Exercise of the option is contingent on securing $3 million in funding or a specific grant (FENG program) by August 31, 2026. A revised grant application was submitted in March 2026.
- IL-17 Program: The company is reassessing the development strategy for its IL-17 NanoAb program due to scientific challenges and a competitive landscape. There is uncertainty regarding the continuation of this program under its current structure.
- Geopolitical Risk: Operations are concentrated in Israel. Ongoing regional conflicts and military campaigns (including recent escalations in early 2026) pose risks to workforce availability, infrastructure, and supply chains.
- Nasdaq Compliance: The company has received notices regarding non-compliance with Nasdaq minimum bid price and stockholders' equity rules in the past. While compliance was regained in 2024 via a reverse split and debt-to-equity conversion, continued monitoring is required.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current cash ($1.7M) against the burn rate and the timeline for the next financing event.
- PC111 Funding Status: Confirm the status of the revised FENG grant application and the ability to meet the $3 million funding condition by August 2026 to exercise the acquisition option.
- CDMO Unit Economics: Assess the path to profitability for the CDMO unit, which currently operates at a loss (Cost of Revenues exceeded Revenues by $2.7M in 2025).
- IL-17 Strategy: Review management's updated strategic plan for the IL-17 program and potential impact on R&D spend.
- Geopolitical Impact: Evaluate the specific impact of the ongoing regional conflict on the company's Jerusalem and Yavne facilities and employee availability.